References:

1Castel V,Grau E,Noguera R,et al.Molecular biology of neuroblastoma\[J\].Clin Transl Oncol,2007, 9(8):478¡ª483.
2Cohn SL,Pearson AD,London WB,et al.The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report\[J\].J Clin Oncol,2009, 27(2): 289¡ª297.
3Bell E,Chen L,Liu T,et al.MYCN oncoprotein targets and their therapeutic potential\[J\].Cancer Lett,2010,12.
4Lu X,Pearson A,Lunec J.The MYCN oncoprotein as a drug development target\[J\].Cancer Lett,2003, 197(1-2):125¡ª130.
5Mo H,Henriksson M.Identification of small molecules that induce apoptosis in a Mycª²dependent manner and inhibit Mycª²driven transformation\[J\].Proc Natl Acad Sci USA, 2006,103(16):6344¡ª6349.
6Burkhart CA,Cheng AJ,Madafiglio J,et al.Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma\[J\].J Natl Cancer Inst,2003,95(18):1394¡ª1403.
7Nara K,Kusafuka T,Yoneda A,et al.Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification\[J\].Int J Oncol,2007,30(5):1189¡ª1196.
8White PS,Thompson PM,Gotoh T,et al. efinition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma\[J\].Oncogene,2005,24(16):2684¡ª2694.
9Okawa ER,Gotoh T,Manne J,et al.Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas\[J\].Oncogene,2008, 27(6):803¡ª810.
10Bagchi A,Papazoglu C,Wu Y,et al.CHD5 is a tumor suppressor at human 1p36\[J\].Cell, 2007,128(3):459¡ª475.
11Fujita T,Igarashi J,Okawa ER,et al.CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas\[J\].J Natl Cancer Inst,2008,100(13): 940¡ª949.
12Munirajan AK,Ando K,Mukai A,et al.KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death\[J\].J Biol Chem,2008,283(36):24426¡ª24434.
13Attiyeh EF,London WB,Mosse YP,et al.Chromosome 1p and 11q deletions and outcome in neuroblastoma\[J\].N Engl J Med,2005,353(21):2243¡ª2253.
14Vandesompele J, Michels E, De Preter K, et al. Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics\[J\].Int J Cancer,2008, 122(5):1177¡ª1182.
15Eckerle I,Muth D,Batzler J,et al.Regulation of BIRC5 and its isoform BIRC5ª²2B in neuroblastoma\[J\].Cancer Lett,2009,285(1):99¡ª107.
16Saitoª²Ohara F,Imoto I,Inoue J,et al.PPM1D is a potential target for 17q gain in neuroblastoma\[J\].Cancer Res,2003, 63(8):1876¡ª1883.
17Yu M,Ohira M,Li Y,et al.High expression of ncRAN, a novel nonª²coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma\[J\].Int J Oncol,2009, 34(4):931¡ª938.
18Vandesompele J,Baudis M,De Preter K,et al.Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma\[J\].J Clin Oncol,2005,23(10):2280¡ª2299.
19Michels E,Hoebeeck J,De Preter K,et al.CADM1 is a strong neuroblastoma candidate gene that maps within a 3ª±72 Mb critical region of loss on 11q23\[J\].BMC Cancer,2008, 8:173.
20Nowacki S,Skowron M,Oberthuer A,et al.Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma\[J\].Oncogene, 2008,27(23):3329¡ª3338.
21Ando K,Ohira M,Ozaki T,et al.Expression of TSLC1,a candidate tumor suppressor genemapped to chromosome 11q23,is downregulated in unfavorable neuroblastoma without promoter hypermethylation\[J\].Int J Cancer,2008,123(9):2087¡ª2094.
22Hoebeeck J,Michels E,Menten B,et al.High resolution tilingª²path BAC array deletion mapping suggests commonly involved 3p21ª²p22 tumor suppressor genes in neuroblastoma and more frequent tumors\[J\].Int J Cancer,2007,120(3):533¡ª538.
23Michalowski MB,de Fraipont F,Plantaz D,et al.Methylation of tumorª²suppressor genes in neuroblastoma: The RASSF1A gene is almost always methylated in primary tumors\[J\].Pediatr Blood Cancer,2008,50(1):29¡ª32.
24Banelli B,Gelvi I,Di Vinci A,et al.Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors\[J\].Oncogene,2005,24(36):5619¡ª5628.
25Alaminos M, Davalos V, Cheung NKV, et al. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst , 2004, 96(16):1208¡ª1219.
26Misawa A,Tanaka S,Yagyu S,et al.RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker\[J\].Br J Cancer,2009,100(2):399¡ª404.
27Brodeur GM.Neuroblastoma: biological insights into a clinical enigma\[J\].Nat Rev Cancer, 2003,3(3):203¡ª216.
28George RE,London WB,Cohn SL,et al.Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study\[J\].J Clin Oncol,2005,23(27): 6466¡ª6473.
29ÕŽ¡,¶­ÁÁ,´Þ»ªÀ×.Éñ¾­Ä¸Ï¸°ûÁöÏà¹Ø»ùÒòµÄÑо¿½øÕ¹\[J\].ÁÙ´²Ð¡¶ùÍâ¿ÆÔÓÖ¾, 2006,5(6): 443¡ª446.
30Ambros PF,Ambros IM,Brodeur GM,et al.International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee\[J\].Br J Cancer,2009,100(9):1471¡ª1482.